Asthma control during long term treatment with regular inhaled salbutamol and salmeterol

Thorax

Volumn 53, Issue 9, 1998, Pages 744-752

  Taylor, D Robin ^a   Town, G Ian ^a   Herbison, G Peter ^a   Boothman Burrell, David ^a   Flannery, Erin M ^a   Hancox, Bob ^a   Harré, Elizabeth ^a   Laubscher, Keith ^a   Linscott, Vivienne ^a   Ramsay, Catriona M ^a   Richards, Geoff ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

Asthma therapy; Salbutamol; Salmeterol

Indexed keywords

FENOTEROL; PLACEBO; SALBUTAMOL; SALMETEROL;

ARTICLE; ASTHMA; CLINICAL STUDY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; HUMAN; INHALATIONAL DRUG ADMINISTRATION; LONG TERM CARE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PEAK EXPIRATORY FLOW; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 15644381143     PISSN: 00406376     EISSN: None     Source Type: Journal    
DOI: 10.1136/thx.53.9.744     Document Type: Article

References (30)

1. Grainger J, Woodman K, Pearce N, et al. Prescribed fenoterol and death from asthma in New Zealand, 1981-1987. A further case-control study. Thorax 1991;46:105-11.
2. Sears MR, Taylor DR, Print CG, et al. Regular inhaled beta-agonist treatment in bronchial asthma. Lancet 1990;336: 1391-6.
3. Taylor DR, Sears MR, Herbison GP, et al. Regular inhaled beta-agonist in asthma: effects on lung function and exacerbations. Thorax 1993;48:134-8.
4. Taylor DR, Sears MR. Regular beta-adrenergic agonists. Evidence not reassurance is what is needed. Chest 1994;106:552-9.
5. Taylor DR, Sears MR, Cockcroft DW. The beta-agonist controversy. Med Clin North Am 1996;80:719-47.
6. Vathenen AS, Knox AJ, Higgins BJ, et al. Rebound increase in bronchial responsiveness after treatment with inhaled terbutaline. Lancet 1988;i:554-8.
7. Sears MR. Epidemiological trends in asthma. Can Respir J 1996;3:261-8.
8. Tattersfield AE. Clinical pharmacology of long-acting beta-receptor agonists. Life Sci 1993;52:2161-9.
9. Woolcock A, Lundback B, Ringdal N, et al. Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. Am J Respir Crit Care Med 1996;153:1481-8.
10. Greening AP, Ind PW, Northfield M, et al. Added salmeterol versus higher dose corricosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Lancet 1994; 344:219-23.
11. Wilding P, Clark M, Coon JT, et al. Effect of long-term treatment with salmeterol on asthma control: a double-blind, randomised cross-over study. BMJ 1997;314:1441-6.
12. Bone RC. A word of caution regarding a new long-acting bronchodilator. JAMA 1994;271:1447-8.
13. Castle W, Fuller R, Hall J, et al. Serevent nationwide surveillance study: comparison of salmeterol with salbutamol in asthmatic patients who require regular bronchodilator treatment. BMJ 1993;306:1034-7.
14. Mann RD, Kubota K, Pearce G, et al. Salmeterol: a study by prescription-event monitoring in a UK cohort of 15,407 patients. J Clin Epidemiol 1996;49:247-50.
15. Pearlman DS, Chervinsky P, LaForce C, et al. A comparison of salmeterol with albuterol in the treatment of mild to moderate asthma. N Engl J Med 1992;327:1420-5.
16. D'Alonzo GE, Nathan RA, Henochowicz S, et al. Salmeterol xinafoate as maintenance therapy compared with albuterol in patients with asthma. JAMA 1994;271:1412-6.
17. Grove A, Lipworth BJ. Bronchodilator subsensitivity to salbutamol after twice daily salmeterol in asthmatic patients. Lancet 1995;346:201-6.
18. 2 adrenoceptor agonist, salmeterol, on airway hyperresponsiveness in patients with mild asthma. N Engl J Med 1992;327:1198-1203.
19. Town GI, Hodges ID, Wilkie AT, et al. A community wide promotion of asthma self-management in New Zealand. Patient Education and Counselling 1995;26:219-24.
20. Higgins BG, Britton JR, Chinn S, et al. The distribution of peak expiratory flow variability in a population sample. Am Rev Respir Dis 1989;140:1368-72.
21. Koch GG. The use of non-parametric methods in the statistical analysis of the two-period change-over design. Biometrics 1972;28:577-84.
22. Woolson RF, O'Gorman TW. A comparison of several tests for censored paired data. Star Med 1992;11:193-208.
23. Boulet LP, Laviolette M, Boucher S, et al. A twelve-week comparison of salmeterol and salbutamol in the treatment of mild-to-moderate asthma: a Canadian multicenter study. J Allergy Clin Immunol 1997;99:13-21.
24. Pauwels RA, Lofdahl CG, Postma DS, et al.Effect of inhaled formoterol and budesonide on exacerbations of asthma. N Engl J Med 1997;337:1405-11.
25. Drazen JM, Israel E, Boushey HA, et al. Comparison of regularly scheduled with as-needed use of albuterol in mild asthma. N Engl J Med 1996;335:841-7.
26. Chapman KR, Kesten S, Szalai JP. Regular vs.as-needed inhaled salbutamol in asthma control. Lancet 1994;343: 1379-82.
27. Suissa S, Blais L, Ernst P. Patterns of increasing beta-agonist use and the risk of fatal or near-fatal asthma Eur Respir J 1994;7:1602-9.
28. 2 agonist salmeterol in mild to moderate asthmatic patients. Thorax 1993;48:1121-4.
29. 2 agonists. Thorax 1996;51: 1051-6.
30. 2 agonists and their impartial assessment. Chest 1996;110:1131-2.